- Home
- JRS vs SLN Comparison
JRS vs SLN Comparison
Compare JRS & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRS | SLN |
|---|---|---|
| Founded | 2001 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.9M | 236.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JRS | SLN |
|---|---|---|
| Price | $7.90 | $5.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 78.3K | ★ 330.6K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.12 | $2.45 |
| 52 Week High | $8.38 | $7.91 |
Technical Indicators
Market Signals| Indicator | JRS | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 49.54 |
| Support Level | $7.56 | $4.56 |
| Resistance Level | $7.89 | $5.98 |
| Average True Range (ATR) | 0.16 | 0.48 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 90.52 | 66.90 |
Price Performance
Historical ComparisonAbout JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.